{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:27:14Z","timestamp":1790166434198,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["bjanaesthesia.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Anaesthesia"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.bja.2023.04.014","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T17:34:46Z","timestamp":1684172086000},"page":"5-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["What is malignant hyperthermia susceptibility?"],"prefix":"10.1016","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8127-1739","authenticated-orcid":false,"given":"Philip M.","family":"Hopkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bja.2023.04.014_bib1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/ALN.0000000000003547","article-title":"Genomic screening for malignant hyperthermia susceptibility","volume":"133","author":"Biesecker","year":"2020","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2023.04.014_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bja.2023.01.008","article-title":"Distinct pathophysiological characteristics in developing muscle from patients susceptible to malignant hyperthermia","volume":"131","author":"Figueroa","year":"2023","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.04.014_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/bmj.2.5806.145","article-title":"Further studies of porcine malignant hyperthermia","volume":"2","author":"Hall","year":"1972","journal-title":"Br Med J"},{"key":"10.1016\/j.bja.2023.04.014_bib4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/bmj.4.5839.526","article-title":"Procaine in malignant hyperpyrexia","volume":"4","author":"Moulds","year":"1972","journal-title":"Br Med J"},{"key":"10.1016\/j.bja.2023.04.014_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/bja\/45.2.131","article-title":"Erythrocyte osmotic fragility in hyperthermia-susceptible swine","volume":"45","author":"Harrison","year":"1973","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.04.014_bib6","first-page":"638","article-title":"A\u00a0new screening test for susceptibility to malignant hyperpyrexia","volume":"45","author":"Ellis","year":"1973","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.04.014_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/bja\/47.1.62","article-title":"Control of the malignant hyperpyrexia syndrome in MHS swine by dantrolene sodium","volume":"47","author":"Harrison","year":"1975","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.04.014_bib8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/bja\/34.6.395","article-title":"Anaesthetic deaths in a family","volume":"34","author":"Denborough","year":"1962","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.04.014_bib9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(70)92069-6","article-title":"Metabolic error of muscle metabolism after recovery from malignant hyperthermia","volume":"2","author":"Kalow","year":"1970","journal-title":"Lancet"},{"key":"10.1016\/j.bja.2023.04.014_bib10","first-page":"721","article-title":"Halothane-induced muscle contracture as a cause of hyperpyrexia","volume":"43","author":"Ellis","year":"1971","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.04.014_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/343559a0","article-title":"Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia","volume":"343","author":"MacLennan","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bja.2023.04.014_bib12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/343562a0","article-title":"Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2","volume":"343","author":"McCarthy","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bja.2023.04.014_bib13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/hmg\/6.6.953","article-title":"A\u00a0genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees","volume":"6","author":"Robinson","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.bja.2023.04.014_bib14","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/bja\/56.11.1267","article-title":"A\u00a0protocol for the investigation of malignant hyperpyrexia (MH) susceptibility","volume":"56","year":"1984","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.04.014_bib15","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1399-6576.1997.tb04820.x","article-title":"In\u00a0vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects","volume":"41","author":"Ording","year":"1997","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.bja.2023.04.014_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bja\/aev225","article-title":"European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility","volume":"115","author":"Hopkins","year":"2015","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.04.014_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1213\/00000539-198910000-00015","article-title":"Standardization of the caffeine halothane muscle contracture test","volume":"69","author":"Larach","year":"1989","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bja.2023.04.014_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00000542-199803000-00006","article-title":"The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry","volume":"88","author":"Allen","year":"1998","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2023.04.014_bib19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1152\/physiolgenomics.00092.2022","article-title":"Muscle transcriptomic circuits linked to periarticular physiology in end-stage osteoarthritis","volume":"54","author":"Drummer","year":"2022","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.bja.2023.04.014_bib20","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1113\/jphysiol.2010.197632","article-title":"Structure to function: muscle failure in critically ill patients","volume":"588","author":"Puthucheary","year":"2010","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.bja.2023.04.014_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/bja\/70.4.397","article-title":"Comparison of in\u00a0vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders","volume":"70","author":"Hopkins","year":"1993","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.04.014_bib22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/mus.880110507","article-title":"Halothane-caffeine contracture testing in neuromuscular diseases","volume":"11","author":"Heiman-Patterson","year":"1988","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bja.2023.04.014_bib23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00005792-198709000-00004","article-title":"Central core disease. Clinical features in 13 patients","volume":"66","author":"Shuaib","year":"1987","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bja.2023.04.014_bib24","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1213\/ANE.0b013e3181b5ae2d","article-title":"Core myopathies and risk of malignant hyperthermia","volume":"109","author":"Klingler","year":"2009","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bja.2023.04.014_bib25","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1073\/pnas.071048198","article-title":"Excitation\u2013contraction uncoupling by a human central core disease mutation in the ryanodine receptor","volume":"98","author":"Avila","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bja.2023.04.014_bib26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.nmd.2013.03.008","article-title":"Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis","volume":"23","author":"Dlamini","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.bja.2023.04.014_bib27","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/jmedgenet-2019-106461","article-title":"Investigating the genetic susceptibility to exertional heat illness","volume":"57","author":"Gardner","year":"2020","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.bja.2023.04.014_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bja.2018.08.009","article-title":"Abnormal calcium signalling and the caffeine-halothane contracture test","volume":"122","author":"Figueroa","year":"2019","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2023.04.014_bib29","first-page":"648","article-title":"An analysis of the predictive probability of the in\u00a0vitro contracture test for determining susceptibility to malignant hyperthermia","volume":"84","author":"Hopkins","year":"1997","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bja.2023.04.014_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.bja.2023.04.014_bib31","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41436-021-01125-w","article-title":"Variant curation expert panel recommendations for RYR1 pathogenicity classifications in malignant hyperthermia susceptibility","volume":"23","author":"Johnston","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.bja.2023.04.014_bib32","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1093\/hmg\/ddac145","article-title":"Updated variant curation expert panel criteria and pathogenicity classifications for 251 variants for RYR1-related malignant hyperthermia susceptibility","volume":"31","author":"Johnston","year":"2022","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.bja.2023.04.014_bib33","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s12630-011-9494-6","article-title":"Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population","volume":"58","author":"Kraeva","year":"2011","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.bja.2023.04.014_bib34","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bja.2018.06.028","article-title":"Genetic epidemiology of malignant hyperthermia in the UK","volume":"121","author":"Miller","year":"2018","journal-title":"Br J Anaesth"}],"container-title":["British Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091223001897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091223001897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:07:01Z","timestamp":1757790421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007091223001897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0007091223001897"],"URL":"https:\/\/doi.org\/10.1016\/j.bja.2023.04.014","relation":{},"ISSN":["0007-0912"],"issn-type":[{"value":"0007-0912","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is malignant hyperthermia susceptibility?","name":"articletitle","label":"Article Title"},{"value":"British Journal of Anaesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bja.2023.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.bja.2023.01.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 British Journal of Anaesthesia. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}